NCT07083193View on ClinicalTrials.gov

A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 20, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

April 30, 2027

Conditions
Ulcerative Colitis
Interventions
DRUG

AC-101

AC-101 tablets will be administered orally.

Trial Locations (1)

510080

RECRUITING

The First Affiliated Hospital,Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Accro Bioscience (Suzhou) Limited

INDUSTRY